Tüdőrák: vizsgálatok itt: Kína

In Kína 1146 Also abroad 2733

1146 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

4. fázisTaking people
Dabrafenib and/or Trametinib Rollover Study
Where
Beijing
Életkor
18 év to 100 év
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
2. fázisTaking people
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Where
Beijing, Hangzhou, Wuhan, Xi’an, Zhengzhou
Életkor
18 év and over
People
430 worldwide
Run by
Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00
3. fázisTaking people
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Where
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Linhai, Nanchang, Nanjing, Neijiang, Ningbo, Shanghai, Suzhou, Wuhan, Xi'an, Zhengzhou
Életkor
18 év and over
People
780 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00
3. fázisTaking people
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiamusi, Jinan, Kunming, Linhai, Linyi, Nanchang, Nanjing, Neijiang, Shanghai, Suzhou, Taiyuan, Ürümqi, Wenzhou, Wuhan, Wuxi, Xiamen, Xi'an, Xian, Zhengzhou
Életkor
18 év and over
People
348 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00
3. fázisTaking people
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Jinan, Linhai, Nanchang, Shanghai, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xi'an
Életkor
18 év and over
People
530 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00
2. fázisTaking people
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Where
Fuzhou, Shanghai, Tianjin, Wuhan
Életkor
18 év and over
People
40 worldwide
Run by
Wayshine Biopharm, Inc.
See details and how to joinNCT06868485
No phaseTaking people
PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
Where
Xi'an
Életkor
18 év to 75 év
People
35
Run by
Xijing Hospital
See details and how to joinNCT06914427
3. fázisTaking people
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Where
Beijing, Changsha, Chengdu, Chongqing, Fujian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiamusi, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Zhengzhou
Életkor
18 év and over
People
675 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00
1/2. fázisTaking people
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
Where
Fuzhou, Shanghai, Tianjin
Életkor
18 év and over
People
48
Run by
Wayshine Biopharm, Inc.
See details and how to joinNCT07206498
2. fázisTaking people
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Where
Chengdu, Nanchang, Nanjing, Shanghai
Életkor
18 év and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07252739 · EU 2025-521939-36-00
3. fázisTaking people
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiamusi, Jinan, Nanchang, Nanjing, Shanghai, Shantou, Shenyang, Tianjin, Wuhan, Xuzhou, Zhengzhou
Életkor
18 év and over
People
400 worldwide
Run by
AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00
3. fázisTaking people
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hshijiazhuang, Jinan, Kunming, Nanchang, Nanning, Ningbo, Shanghai, Urumuqi, Wuhan
Életkor
18 év and over
People
400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00
3. fázisTaking people
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Where
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou
Életkor
18 év and over
People
670 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00
2. fázisTaking people
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
Where
Shanghai
Életkor
18 év and over
People
19
Run by
Shanghai Chest Hospital
See details and how to joinNCT07549061
3. fázisTaking people
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Linhai, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Ürümqi, Wenzhou, Wuhan, Xiamen
Életkor
18 év and over
People
310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00
3. fázisTaking people
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Where
Anyang, Beijing, Binzhou, Changsha, Changsha Shi, Chengdu, Chongqing, Dazhou Shi, Dongguan Shi, Fuzhou, Guangzhou, Guilin, Guiyang, Haikou, Hangzhou, Harbin, Jiangmen, Jinan, Jingzhou, Lianyungang, Linyi, Nanjing, Nanning, Shanghai Shi, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang Shi, Weihui Shi, Wuhan, Xi'an, Yibin, Zhengzhou, Zhongshan
Életkor
18 év and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680790 · EU 2026-526486-21-00
1/2. fázisTaking people
A Study of DS-3939a in Participants With Solid Tumors
Where
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Hexi District, Tianjin, Jiamusi, Jinan, Linyi, Shanghai, Taizhou, Wuhan, Zhengzhou
Életkor
18 év and over
People
400 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07739966 · EU 2026-525218-75-00
1/2. fázisTaking people
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
Where
Chengdu, Harbin, Shanghai
Életkor
18 év and over
People
55 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07843940 · EU 2026-525459-99-00
No phaseNot yet taking people in Kína
Clinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung Cancer
Where
Beijing
Életkor
18 év and over
People
224
Run by
LI FENG
See details and how to joinNCT07928882
3. fázisTaking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Huai'an, Huizhou, Jinan, Linhai, Liuzhou, Nanchang, Nanning, Neijiang, Shanghai, Shenyang, Taiyuan, Tianjin, Wanzhou, Wuhan, Xi'an, Xinxiang, Zhengzhou
Életkor
18 év and over
People
1000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
2. fázisTaking people
Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
Where
Guangzhou
Életkor
18 év to 80 év
People
69
Run by
The First Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06926790
1/2. fázisTaking people
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Where
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangmen, Nanchang, Shanghai, Taizhou
Életkor
18 év to 64 év
People
170 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07227597 · EU 2025-521032-11-00
2. fázisTaking people
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Where
Guangzhou, Shanghai
Életkor
18 év and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07486817 · EU 2025-523567-38-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Beijing, Changchun, Chengdu, Foshan, Guangzhou, Hangzhou, HangzhouZhejiang, Hefei, Jinan, Nanchang, Nanjing, Shenzhen, Suzhou, Taizhou, Tianjin
Életkor
18 év and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
3. fázisTaking people
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Where
Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanning, Suzhou, Taiyuan
Életkor
18 év and over
People
356 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00